Active Recombinant Human CD40, Fc-tagged, Biotinylated
Cat.No. : | CD40-577H |
Product Overview : | The recombinant human CD40-Fc fusion is expressed as a 401 amino acid protein consisting of Glu21 - Arg193 region of CD40 (UniProt accession #P25942) and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions. |
- Specification
- Gene Information
- Related Products
Source : | Human cells |
Species : | Human |
Tag : | Fc |
Form : | Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free). The purified recombinant protein was labeled with Biotin (3-5 Biotin per molecule). |
Bio-activity : | Binds to its ligand CD40L/CD154 and inhibits CD40L--induced signaling activity including NF-κB activation and proliferation of human B cells. |
Molecular Mass : | Calculated molecular mass (kDa): 44.7; Estimated by SDS-PAGE under reducing condition (kDa): 55-60 |
Endotoxin : | <0.1 eu per 1 μg of purified recombinant protein determined by the |
Purity : | >95% judged by SDS-PAGE under reducing condition |
Storage : | The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks. Avoid repeated freeze-thaw cycles. |
Gene Name : | CD40 CD40 molecule, TNF receptor superfamily member 5 [ Homo sapiens ] |
Official Symbol : | CD40 |
Synonyms : | CD40; CD40 molecule, TNF receptor superfamily member 5; TNFRSF5, tumor necrosis factor receptor superfamily, member 5; tumor necrosis factor receptor superfamily member 5; Bp50; p50; CD40L receptor; CD40 type II isoform; B cell-associated molecule; B cell surface antigen CD40; B-cell surface antigen CD40; CD40 antigen (TNF receptor superfamily member 5); tumor necrosis factor receptor superfamily, member 5; nerve growth factor receptor-related B-lymphocyte activation molecule; CDW40; TNFRSF5; MGC9013; |
Gene ID : | 958 |
mRNA Refseq : | NM_001250 |
Protein Refseq : | NP_001241 |
MIM : | 109535 |
UniProt ID : | P25942 |
Chromosome Location : | 20q12-q13.2 |
Pathway : | Adaptive Immune System, organism-specific biosystem; Allograft rejection, organism-specific biosystem; Allograft rejection, conserved biosystem; Asthma, organism-specific biosystem; Asthma, conserved biosystem; Autoimmune thyroid disease, organism-specific biosystem; Autoimmune thyroid disease, conserved biosystem; |
Function : | enzyme binding; protein binding; receptor activity; signal transducer activity; |
Products Types
◆ Recombinant Protein | ||
Cd40-8727R | Recombinant Rat Cd40 protein(Met1-Arg193), His-tagged | +Inquiry |
CD40-07H | Recombinant Human CD40 Protein, hIgG/His-tagged | +Inquiry |
CD40-633R | Recombinant Rhesus macaque CD40 Protein, Fc-tagged | +Inquiry |
Cd40-1462M | Recombinant Mouse Cd40 Protein, His (Fc)-Avi-tagged | +Inquiry |
CD40-371H | Active Recombinant Human CD40 Protein, Fc & Avi-tagged, Biotinylated | +Inquiry |
◆ Lysates | ||
CD40-1831MCL | Recombinant Mouse CD40 cell lysate | +Inquiry |
CD40-2617HCL | Recombinant Human CD40 cell lysate | +Inquiry |
CD40-1262RCL | Recombinant Rat CD40 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionCD40 agonists have the potential to enhance immune responses against infectious agents, but their clinical use in this context is an area of ongoing research.
As of my knowledge cutoff date in January 2022, there were no FDA-approved drugs specifically targeting CD40. However, clinical trials were ongoing for CD40-targeted therapies.
Yes, CD40-targeted therapies are often investigated in combination with other treatments like checkpoint inhibitors or chemotherapy to enhance their effectiveness.
Side effects may include flu-like symptoms, cytokine release syndrome, and immune-related adverse events, which can be managed with supportive care and close monitoring.
Research on CD40-targeted therapies for atherosclerosis is still in the experimental stages and not yet in advanced clinical trials.
Customer Reviews (3)
Write a reviewIts utilization in this technique has allowed for precise visualization and determination of protein structures with remarkable clarity and resolution.
The reliable and high-quality results obtained using CD40 protein make it an excellent choice for researchers studying protein structures.
CD40 protein has proved to be an invaluable tool in protein electron microscopy structure analysis.
Ask a Question for All CD40 Products
Required fields are marked with *
My Review for All CD40 Products
Required fields are marked with *
Inquiry Basket